-$0.26 Earnings Per Share Expected for ProQR Therapeutics (NASDAQ:PRQR) This Quarter

Analysts predict that ProQR Therapeutics (NASDAQ:PRQRGet Rating) will announce earnings per share of ($0.26) for the current quarter, Zacks reports. Two analysts have made estimates for ProQR Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.27). ProQR Therapeutics reported earnings per share of ($0.29) during the same quarter last year, which would suggest a positive year-over-year growth rate of 10.3%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that ProQR Therapeutics will report full-year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($1.00) to ($0.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.98) to ($0.51). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for ProQR Therapeutics.

ProQR Therapeutics (NASDAQ:PRQRGet Rating) last posted its earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). ProQR Therapeutics had a negative return on equity of 54.60% and a negative net margin of 2,469.79%. The firm had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.90 million.

Several research analysts have commented on the stock. HC Wainwright dropped their price objective on shares of ProQR Therapeutics from $4.00 to $2.00 in a report on Monday, May 9th. StockNews.com raised shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 9th. Stifel Nicolaus downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $20.00 to $3.00 in a research note on Friday, February 11th. JMP Securities lowered their target price on shares of ProQR Therapeutics from $8.00 to $5.00 and set a “market outperform” rating for the company in a research note on Thursday, April 14th. Finally, Chardan Capital lowered their target price on shares of ProQR Therapeutics from $8.00 to $2.50 and set a “buy” rating for the company in a research note on Thursday, April 14th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Buy” and an average price target of $6.59.

PRQR traded up $0.02 during mid-day trading on Monday, reaching $0.69. 23,382 shares of the company traded hands, compared to its average volume of 1,592,608. The stock has a market capitalization of $48.91 million, a P/E ratio of -0.64 and a beta of 0.97. The company has a quick ratio of 6.94, a current ratio of 7.27 and a debt-to-equity ratio of 0.38. The company’s fifty day moving average price is $0.81 and its 200-day moving average price is $3.89. ProQR Therapeutics has a 52-week low of $0.53 and a 52-week high of $9.09.

Several hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP grew its stake in ProQR Therapeutics by 123.5% during the 3rd quarter. GSA Capital Partners LLP now owns 137,003 shares of the biopharmaceutical company’s stock valued at $1,147,000 after acquiring an additional 75,714 shares in the last quarter. Altium Capital Management LP acquired a new position in ProQR Therapeutics in the 3rd quarter valued at about $1,046,000. Copernicus Capital Management LLC acquired a new position in ProQR Therapeutics in the 3rd quarter valued at about $335,000. Opaleye Management Inc. boosted its holdings in ProQR Therapeutics by 3.2% in the 3rd quarter. Opaleye Management Inc. now owns 1,424,200 shares of the biopharmaceutical company’s stock valued at $11,921,000 after purchasing an additional 43,800 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in ProQR Therapeutics in the 3rd quarter valued at about $321,000.

About ProQR Therapeutics (Get Rating)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.

Featured Articles

Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.